Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
暂无分享,去创建一个
Majid E Warkiani | James B. Freeman | M. Millward | M. Ziman | M. Warkiani | E. Gray | M. Khattak | T. Meniawy | M. Frank | Carlos A Aya-Bonilla | Gabriela Marsavela | James B Freeman | Chris Lomma | Markus H Frank | Muhammad A Khattak | Tarek M Meniawy | Michael Millward | Elin S Gray | Mel Ziman | G. Marsavela | Chris Lomma | C. Aya-Bonilla
[1] Jongyoon Han,et al. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics , 2015, Nature Protocols.
[2] M. Ziman,et al. PAX3 Expression in Normal Skin Melanocytes and Melanocytic Lesions (Naevi and Melanomas) , 2010, PloS one.
[3] Rika Deraemaecker,et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.
[4] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[5] T. Luger,et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. , 2011, The Journal of investigative dermatology.
[6] Sridhar Ramaswamy,et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.
[7] J. Blake,et al. Pax3 transcripts in melanoblast development , 2005, Development, growth & differentiation.
[8] Eugene J. Lim,et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples , 2014, Nature Protocols.
[9] Mohamed H. Sayegh,et al. Identification of cells initiating human melanomas , 2008, Nature.
[10] Bo Lu,et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood , 2011, Biomedical microdevices.
[11] M. Ziman,et al. PAX3 across the spectrum: from melanoblast to melanoma , 2009, Critical reviews in biochemistry and molecular biology.
[12] N. Dhomen,et al. Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. , 2016, Cancer discovery.
[13] John Hines,et al. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System , 2015, PloS one.
[14] Sumitra Mohan,et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. , 2016, The Analyst.
[15] G. Boyle,et al. Mechanisms Contributing to Differential Regulation of PAX3 Downstream Target Genes in Normal Human Epidermal Melanocytes versus Melanoma Cells , 2015, PloS one.
[16] C. Ni,et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis , 2016, Clinical and Translational Oncology.
[17] K. O'Byrne,et al. Short term ex-vivo expansion of circulating head and neck tumour cells , 2016, Oncotarget.
[18] A. Giblin,et al. Incidence, mortality and survival in cutaneous melanoma. , 2007, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[19] James B. Freeman,et al. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells , 2012, Journal of Translational Medicine.
[20] K. Flaherty,et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. , 2015, European journal of cancer.
[21] M. Gore,et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Q. Zhan,et al. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. , 2014, Cancer research.
[23] Anil K Sood,et al. A novel platform for detection of CK+ and CK- CTCs. , 2011, Cancer discovery.
[24] Jongyoon Han,et al. An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. , 2014, The Analyst.
[25] Sridhar Ramaswamy,et al. Isolation and molecular characterization of circulating melanoma cells. , 2014, Cell reports.
[26] M. Millward,et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression , 2013, The British journal of dermatology.
[27] H. Rizos,et al. Differential PAX3 functions in normal skin melanocytes and melanoma cells. , 2011, Biochemical and biophysical research communications.
[28] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[29] Jedd D. Wolchok,et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2016 .
[30] Mehmet Toner,et al. Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.
[31] Daniela Massi,et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. , 2010, The Journal of investigative dermatology.
[32] Tuan Zea Tan,et al. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy , 2015, Oncotarget.
[33] P. Lorigan,et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. , 2013, The Journal of investigative dermatology.
[34] Ali Asgar S. Bhagat,et al. Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells , 2014, PloS one.
[35] Tanja Fehm,et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.
[36] K. Isselbacher,et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip , 2010, Proceedings of the National Academy of Sciences.
[37] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Flaherty,et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.
[39] James B. Freeman,et al. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma , 2014, BMC Cancer.
[40] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Schlomm,et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients , 2016, Scientific Reports.
[42] D. Schadendorf,et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. , 2016 .
[43] C. Shea,et al. PAX3 expression in primary melanomas and nevi , 2008, Modern Pathology.
[44] Sridhar Ramaswamy,et al. A microfluidic device for label-free, physical capture of circulating tumor cell-clusters , 2015, Nature Methods.
[45] P. Lorigan,et al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma , 2014, Melanoma research.
[46] Peter C. Y. Chen,et al. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. , 2014, Lab on a chip.
[47] J. Wenner,et al. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. , 2015, Cancer letters.
[48] J. Annereau,et al. Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells , 2012, PloS one.
[49] Li Wang,et al. Microfluidic device with integrated microfilter of conical-shaped holes for high efficiency and high purity capture of circulating tumor cells , 2014, Scientific Reports.
[50] Melanie Ziman,et al. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. , 2015, Clinical biochemistry.
[51] T. Wobbes,et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.
[52] M. Millward,et al. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment , 2015, The Journal of investigative dermatology.
[53] J. Epstein,et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation , 2005, Nature.
[54] K. Pantel,et al. Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.
[55] Sridhar Ramaswamy,et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.